Boehringer, Lilly launch Trajenta in U.K.; Pfizer ends Icagen tender with 70% of shares;

@FiercePharma: FTC's nosing around Valeant's deals to buy Dermik and Ortho Dermatologics, but $VRX still expects to close this year. Release | Follow @FiercePharma

> Boehringer Ingelheim and Eli Lilly ($LLY) have launched their new diabetes drug Trajenta in the U.K. News

> Pfizer ($PFE) has wrapped up its second Icagen tender offer with more than 70% of the company's shares. This move paves the way for a second-step merger to make Icagen a wholly-owned subsidiary. Pfizer release

> Even though Republican presidential candidate Michele Bachmann's claims about HPV vaccines are erroneous, they still could seriously disrupt efforts to have young people vaccinated against the virus that can cause cervical and other cancers. Story

> Forest Laboratories ($FRX) shares dropped after a Goldman Sachs analyst downgraded the stock to "sell" from "neutral." Report

> Mylan's ($MYL) Matrix Laboratories unit won tentative FDA approval for a co-packaged generic AIDS cocktail, with nevirapine and a one-pill combo of lamivudine and tenofovir, together in one box. Mylan release

> Lupin Pharmaceuticals won final FDA approval for its generic version of Watson Pharmaceuticals' contraceptive NOR-QD. News

> Five consumer groups are banding together to express to the FTC their worries about a proposed merger of pharmacy benefits managers Express Scripts ($ESRX) and Medco Health Solutions ($MHS). Item

> AstraZeneca ($AZN) purchased another 850,000 of its shares at 2804 pence each as part of its ongoing buyback plan. Report

Biotech News

@FierceBiotech: JDRF presents a $100,000 challenge for breakthrough ideas on diabetes. Item | Follow @FierceBiotech

@JohnCFierce:  Tokai (Cambridge, MA) lands new CEO, $23M venture round for PhIIb cancer study. Report | Follow @JohnCFierce

@RyanMFierce:  I hope to see lots of Boston biotechies at Oct. 19 breakfast featuring R&D heads at Biogen, Vertex and @JohnCFierce. Info | Follow @RyanMFierce

@MaureenFierce: Giving flu vaccine to kids 2 to 4 cuts ER visits for flu-like symptoms by a third. Story | Follow @MaureenFierce

 @FierceMedDev: Varian Medical Systems inks deal to buy Calypso Medical Technologies. Release | Follow @FierceMedDev

> Obama deficit plan rolls back biotech marketing exclusivity to 7 years. Item

> Tokai lands new CEO, $23M venture round for PhIIb cancer study. News

> NIH launches $140M drug tox project, hunts for translational R&D chief. Story 

Biotech Research News

> UM cuts the ribbon on new biomed research site. Report 

> NIH supports "super" antioxidant program to shield against sun risks. News 

> JDRF presents a $100,000 challenge for breakthrough ideas on diabetes. Article 

> Green dye lights up hidden ovarian tumor targets for cancer surgeons. Item

Manufacturing News

> Offshore generics makers eye biosimilars. Report 

> Pharma discharge study reveals big impact on fish. News 

> Flying high on Elan deal, Alkermes gets to work on Big Pharma project. Story 

> Genzyme's shortage opens door to rival Protalix. Article 

> SCM flexes formulation muscle for Mitovie. News 

> Sun gets NJ plant back on GMP track, still working on Detroit facility. Piece 

And Finally... The cost of obesity and other lifestyle-linked illnesses will approach $47 trillion by 2030, a new study found. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.